Chapman-Davis E et al. Identifying disparities in gynecologic cancer: Results and analysis from a patient preference survey. ASCO 2022;Abstract 5561.

Corvigno S et al. Immune microenvironment composition in high-grade serous ovarian cancers based on BRCA mutational status. J Cancer Res Clin Oncol 2021;147(12):3545-55. Abstract

Fleming ND et al. Correlation of surgeon radiology assessment with laparoscopic disease site scoring in patients with advanced ovarian cancer. Int J Gynecol Cancer 2021;31(1):92-7. Abstract

Gershenson DM et al. The genomic landscape of low-grade serous ovarian/peritoneal carcinoma and its impact on clinical outcomes. Gynecol Oncol 2022;165(3):560-7. Abstract

Handley K et al. Frailty repels the knife: The impact of frailty index on surgical intervention and outcomes. Gynecol Oncol 2022;166(1):50-6. Abstract

Hinchcliff E et al. Current and future landscape of poly (ADP-ribose) polymerase inhibition resistance. Curr Opin Obstet Gynecol 2021;33(1):19-25. Abstract

Monk BJ et al. A randomized, phase III trial to evaluate rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45). J Clin Oncol 2022;[Online ahead of print]. Abstract

Monk BJ et al. ATHENA–MONO (GOG-3020/ENGOT-ov45): A randomized, double-blind, phase 3 trial evaluating rucaparib monotherapy versus placebo as maintenance treatment following response to first-line platinum-based chemotherapy in ovarian cancer. ASCO 2022;Abstract LBA5500.

Pham MM et al. The clinical challenges, trials, and errors of combatting poly(ADP-ribose) polymerase inhibitors resistance. Cancer J 2021;27(6):491-500. Abstract

Secord AA et al. Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review. Gynecol Oncol 2021;162(2):482-95. Abstract

Sims TT et al. Correlation of HRD status with clinical and survival outcomes in patients with advanced-stage ovarian cancer. ASCO 2021;Abstract 5568.